Harry W. Findley

2.1k total citations
54 papers, 1.8k citations indexed

About

Harry W. Findley is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Harry W. Findley has authored 54 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 22 papers in Immunology and 18 papers in Oncology. Recurrent topics in Harry W. Findley's work include Acute Lymphoblastic Leukemia research (16 papers), Cancer-related Molecular Pathways (14 papers) and Cell death mechanisms and regulation (13 papers). Harry W. Findley is often cited by papers focused on Acute Lymphoblastic Leukemia research (16 papers), Cancer-related Molecular Pathways (14 papers) and Cell death mechanisms and regulation (13 papers). Harry W. Findley collaborates with scholars based in United States, Canada and South Korea. Harry W. Findley's co-authors include Lubing Gu, Muxiang Zhou, Ningxi Zhu, William G. Woods, Andrew M. Yeager, Fengzhi Li, Mei Zhou, Nianyong Zhu, Carlos S. Alvarado and Abdelsalam H. Ragab and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Harry W. Findley

54 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry W. Findley United States 23 1.1k 634 447 254 237 54 1.8k
Katja Pokrovskaja Tamm Sweden 30 1.3k 1.2× 1.0k 1.6× 606 1.4× 268 1.1× 200 0.8× 62 2.4k
Peter R. Strack United States 20 2.1k 2.0× 808 1.3× 334 0.7× 518 2.0× 211 0.9× 34 2.8k
Scott Wardwell United States 15 1.6k 1.5× 386 0.6× 644 1.4× 192 0.8× 241 1.0× 22 2.4k
Valerie I. Brown United States 21 727 0.7× 515 0.8× 298 0.7× 91 0.4× 333 1.4× 44 1.5k
Maya Dajee United States 15 1.2k 1.2× 628 1.0× 434 1.0× 354 1.4× 305 1.3× 23 2.0k
Sylvie Giuriato France 21 1.3k 1.2× 388 0.6× 419 0.9× 299 1.2× 450 1.9× 35 2.2k
K. Ariail United States 8 1.9k 1.8× 611 1.0× 891 2.0× 623 2.5× 95 0.4× 10 2.6k
Xin He China 27 1.3k 1.3× 456 0.7× 500 1.1× 576 2.3× 106 0.4× 132 2.4k
Melanie J. McConnell New Zealand 25 968 0.9× 245 0.4× 314 0.7× 179 0.7× 207 0.9× 49 1.6k
L Shi Canada 7 1.2k 1.2× 296 0.5× 615 1.4× 140 0.6× 100 0.4× 8 1.7k

Countries citing papers authored by Harry W. Findley

Since Specialization
Citations

This map shows the geographic impact of Harry W. Findley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry W. Findley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry W. Findley more than expected).

Fields of papers citing papers by Harry W. Findley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry W. Findley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry W. Findley. The network helps show where Harry W. Findley may publish in the future.

Co-authorship network of co-authors of Harry W. Findley

This figure shows the co-authorship network connecting the top 25 collaborators of Harry W. Findley. A scholar is included among the top collaborators of Harry W. Findley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry W. Findley. Harry W. Findley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Findley, Harry W., et al.. (2011). A Switching Mechanism in Doxorubicin Bioactivation Can Be Exploited to Control Doxorubicin Toxicity. PLoS Computational Biology. 7(9). e1002151–e1002151. 43 indexed citations
2.
Findley, Harry W., et al.. (2010). The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemotherapy and Pharmacology. 68(2). 325–335. 30 indexed citations
3.
Dasgupta, Anindya, Carlos S. Alvarado, Zhiheng Xu, & Harry W. Findley. (2010). Expression and functional role of inhibitor-of-apoptosis protein livin (BIRC7) in neuroblastoma. Biochemical and Biophysical Research Communications. 400(1). 53–59. 22 indexed citations
4.
Gu, Lubing, Kuang‐Yueh Chiang, Ningxi Zhu, Harry W. Findley, & Muxiang Zhou. (2007). Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Experimental Hematology. 35(6). 957–966. 29 indexed citations
5.
Zhu, Ningxi, Lubing Gu, Harry W. Findley, et al.. (2006). KLF5 Interacts with p53 in Regulating Survivin Expression in Acute Lymphoblastic Leukemia. Journal of Biological Chemistry. 281(21). 14711–14718. 101 indexed citations
6.
Zhu, Ningxi, et al.. (2005). Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochemical and Biophysical Research Communications. 335(4). 1272–1279. 28 indexed citations
7.
Jiang, Rong, Lubing Gu, Harry W. Findley, & Muxiang Zhou. (2004). Loss of PTEN expression induces NF-kB via PI3K/Akt pathway involving resistance to chemotherapy in acute lymphoblastic leukemia cell lines. Cancer Research. 64. 1277–1277. 1 indexed citations
8.
Gu, Lubing, Ningxi Zhu, Harry W. Findley, & Muxiang Zhou. (2004). Loss of PTEN Expression Induces NF-kB Via PI3K/Akt Pathway Involving Resistance to Chemotherapy in Acute Lymphoblastic Leukemia Cell Lines.. Blood. 104(11). 4438–4438. 8 indexed citations
9.
Zhou, Muxiang, Lubing Gu, Ningxi Zhu, William G. Woods, & Harry W. Findley. (2003). Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene. 22(50). 8137–8144. 48 indexed citations
10.
Zhang, Zhixin, Michael Zemlin, Yui‐Hsi Wang, et al.. (2003). Contribution of VH Gene Replacement to the Primary B Cell Repertoire. Immunity. 19(1). 21–31. 86 indexed citations
11.
Zhou, Muxiang, Lubing Gu, Harry W. Findley, Rong Jiang, & William G. Woods. (2003). PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.. PubMed. 63(19). 6357–62. 95 indexed citations
12.
Findley, Harry W., et al.. (2002). Comparison of DR5 and Fas expression levels relative to the chemosensitivity of acute lymphoblastic leukemia cell lines. Leukemia Research. 26(5). 503–513. 8 indexed citations
13.
14.
Afify, Zeinab, et al.. (1990). Cytotoxicity of purified leu 19+ cells from the peripheral blood of children with acute lymphocytic leukemia. Cancer. 66(3). 469–473. 3 indexed citations
15.
16.
17.
18.
Findley, Harry W., et al.. (1987). Natural killer cells in children with acute leukemia. The effect of interleukin-2. Cancer. 60(12). 2913–2918. 16 indexed citations
19.
Williams, D.L., et al.. (1987). Cyclosporine in the Treatment of Red Cell Aplasia. Journal of Pediatric Hematology/Oncology. 9(4). 314–316. 10 indexed citations
20.
Parmley, Richard T., William M. Crist, Abdelsalam H. Ragab, et al.. (1981). Phagocytosis of neutrophils by marrow macrophages in childhood chronic benign neutropenia. The Journal of Pediatrics. 98(2). 207–212. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katja Pokrovskaja Tamm Breakdown of academic impact, for papers by Peter R. Strack Breakdown of academic impact, for papers by Scott Wardwell Breakdown of academic impact, for papers by Valerie I. Brown Breakdown of academic impact, for papers by Maya Dajee Breakdown of academic impact, for papers by Sylvie Giuriato Breakdown of academic impact, for papers by K. Ariail Breakdown of academic impact, for papers by Xin He Breakdown of academic impact, for papers by Melanie J. McConnell Breakdown of academic impact, for papers by L Shi
Rankless by CCL
2026